Impact of miRNA in Atherosclerosis.

Yao Lu,Tanuja Thavarajah,Wenduo Gu,Jingjing Cai,Qingbo Xu

DOI: https://doi.org/10.1161/ATVBAHA.118.310227

2018-01-01

Arteriosclerosis Thrombosis and Vascular Biology

Abstract:HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 38, No. 9Impact of miRNA in Atherosclerosis Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBImpact of miRNA in Atherosclerosis Yao Lu, Tanuja Thavarajah, Wenduo Gu, Jingjing Cai and Qingbo Xu Yao LuYao Lu From the Center of Clinical Pharmacology (Y.L.) *These authors contributed equally to this article. Search for more papers by this author , Tanuja ThavarajahTanuja Thavarajah School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre, United Kingdom (T.T., W.G., Q.X.). *These authors contributed equally to this article. Search for more papers by this author , Wenduo GuWenduo Gu School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre, United Kingdom (T.T., W.G., Q.X.). Search for more papers by this author , Jingjing CaiJingjing Cai Correspondence to Qingbo Xu, MD, PhD, School of Cardiovascular Medicine and Sciences, King’s College British Heart Foundation Centre, 125 Coldharbour Ln, London SE5 9NU, United Kingdom, Email E-mail Address: [email protected] or Jingjing Cai, MD, Department of Cardiology, Third Xiangya Hospital, Central South University, 138 Tong-Zi-Po Rd, Changsha, Hunan 410013, China, Email E-mail Address: [email protected] Department of Cardiology (J.C., Q.X.), Third Xiangya Hospital, Central South University, Changsha, China Search for more papers by this author and Qingbo XuQingbo Xu Correspondence to Qingbo Xu, MD, PhD, School of Cardiovascular Medicine and Sciences, King’s College British Heart Foundation Centre, 125 Coldharbour Ln, London SE5 9NU, United Kingdom, Email E-mail Address: [email protected] or Jingjing Cai, MD, Department of Cardiology, Third Xiangya Hospital, Central South University, 138 Tong-Zi-Po Rd, Changsha, Hunan 410013, China, Email E-mail Address: [email protected] Department of Cardiology (J.C., Q.X.), Third Xiangya Hospital, Central South University, Changsha, China School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre, United Kingdom (T.T., W.G., Q.X.). Search for more papers by this author Originally published22 Aug 2018https://doi.org/10.1161/ATVBAHA.118.310227Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38:e159–e170miRNAs have received most of the attention during the last decades in particular for their role in tempering gene expression. An increasing number of studies highlighting the importance of miRNAs in the development and progression of atherosclerosis have been performed. Recently, it was shown that miRNAs exert their role in the pathophysiology of atherosclerosis via the regulation of atherosclerosis-prone genes, as well as their impact in regulating post-transcriptional gene expression. Hence, by affecting the level of synthesized protein within cells, they may be significant in driving the dysregulation that affects endothelial cells, smooth muscle cells, and leukocytes, which initiates and augments the growth of an atherosclerotic plaque. Furthermore, the circulating levels of vascular cell-enriched miRNAs in patients could serve as a marker of disease severity and phenotypes. The accumulating evidence also indicates that their effects on atherosclerosis may allow us to exploit miRNAs as novel therapeutics or clinical biomarkers that may lead to better management of vascular diseases. Current reports providing insights into the impact of miRNAs and the mechanisms of their influences in atherosclerosis are reviewed here with a particular emphasis on studies that have been recently published in Arteriosclerosis, Thrombosis, and Vascular Biology.miRNAs are defined as short, single-stranded, noncoding RNA molecules, which influence the synthesis of proteins, via their interactions with mRNAs.1,2 They are believed to comprise about 1% to 5% of the human genome and are theorized to be evolutionarily conserved components, which control the post-transcriptional expression of certain genes.2–4 Through this action, the miRNA will be able to inhibit, and hence influence, certain protein expression by attaching to and silencing this gene. The miRNA suppresses the gene expression either via cleaving and degrading its subsequent target mRNA or by inhibiting the translation process. The mode of action used to silence the gene is determined by the degree of complementarity that occurs between the miRNA complex and its target mRNA.5Atherosclerosis refers to the chronic inflammatory disease, which involves the accumulation of lipid engorged macrophages in the subendothelial layer of arterial vessels.6,7 It is widely recognized that monocyte adhesion is provoked by endothelial dysfunction of the arterial wall, on which they will differentiate into macrophages that will engulf lipoprotein particles to become foam cells.8,9 This process of lipid accumulation induces the inflammation, which drives and augments the atherosclerotic process, resulting in a fatal positive feedback loop.10 This response to endothelial injury is also believed to be the cause of restenosis, after treatments for severe atherosclerotic disease.11 Arteriosclerosis includes the so-called pathology of accelerated atherosclerosis seen after interventions such as heart transplants, coronary vein grafts, and percutaneous coronary interventions.12 We can consider 3 processes attributing to the reduction of a lumen size: elastic recoil, arterial remodeling, and intimal thickening. It is believed that the cause of arteriosclerosis, after these procedures, is attributed to the formation of neointima.13 The pathophysiology of this lesion development is believed to be etiologically similar to the vascular injury response, which led to the formation of the primary atherosclerotic lesions, and hence, there is an accumulation of SMCs.14 Over time, this continuous growth of the neointima can lead to restenosis and, if it results in full occlusion, will cause ischemia to the distal tissue and muscles served by this artery. Although a significant progress for the pathogenesis of arteriosclerosis has been made, the molecular mechanisms of cell responses are not fully understood.Because miRNAs play an important role in silencing their target genes, which will subsequently reduce their protein synthesis and hence effect the function of the cells, it has, therefore, been hypothesized that miRNAs may in fact play a role in endothelial injury and consequent cell attachment, growth, and inflammatory responses.3,15–17 Moreover, it has been suggested that miRNAs may act as critical regulators of smooth muscle proliferation and phenotypic change,18–21 as well as influencing macrophage activity. Thus, by understanding the influence that miRNAs have on these cells driving the progression of arteriosclerosis, their role in the process of vascular disease and potential use within clinical therapy could be important.Biogenesis and Target Recognition of miRNAsmiRNA biogenesis is a multistep process, beginning from the initial transcription of primary miRNA, which has a hairpin/stem-loop structure. After being transcribed with RNA polymerase II or RNA polymerase III, primary miRNAs were first processed in the nucleus through Drosha/DGCR8 microprocessor complex in a sequence-independent but structural-dependent manner to form the precursor miRNA around 60 to 80 nucleotides long.22 Afterward, precursor miRNAs were actively exported to the cytoplasm with exportin-5 in a Ran-GTP–dependent manner. In the cytoplasm, the transition of GTP to GDP aids to release the precursor miRNAs from exportin-5. Subsequently, Dicer works cooperatively with TRBP (RNA-induced silencing complex) to cleave the precursor miRNA and generate mature miRNAs, which will be incorporated into the RISC complex and then bind to the 3′-untranslated region (3′-UTR) of the target sequence in a complementary manner to induce target mRNA degradation or translation inhibition.It was determined that the 5′ end of miRNA was more conserved than the 3′ end, with this conservation significantly contributing to better target prediction. Further sequence alignment across different species showed a frequently conserved A in the target mRNA 3′-UTR immediately downstream of the sequence that was complimentary to the seed site.23 This conserved A was named A1. Because nucleotide A could not always bind to the first nucleotide of miRNA in a Watson-Crick base pair-matched manner, it was proposed that this conserved nucleotide A could be recognized by proteins in the RISC. Collectively, the target sites described could be separated into 2 groups according to their location on miRNAs. The first group mainly includes the seed site centered ones located at the 5′ end of miRNAs: 8mer site, 7mer-A1 site, 7mer-m8 site, and 7mer site, which could be called canonical sites of miRNAs for target prediction. Efforts have also been invested to identify 6mer and offset 6mer sites.24 The second group was 3′ supplementary site and 3′ compensatory site, which, as suggested by the nomenclature, locates at the 3′ end of miRNAs.Apart from the differing sites on miRNAs, including the canonical ones and the noncanonical ones, seedless inhibition of miRNA on mRNA was also observed, implying that the whole system of miRNA regulation mechanism might be more complex than we have already described. E2F2 gene could be directly inhibited by miR-24 through seedless 3′-UTRs.25 Additionally, as aforementioned, perfect canonical seed sites were not sufficient to predict the functional interaction between miRNA and its target mRNAs. It must be considered that there may also be other factors influencing the interaction process. Argonaute 2 protein is an important component of the RISC complex. It was demonstrated by structural studies that it displayed a flexible structure, which could be stabilized by miRNAs binding to it.26 Another element that influences the interaction process, is the mRNA accessibility to binding sites.27 Binding of the target site on mRNAs with RBP (RNA-binding protein) or the inclusion of target site within the stem-loop structures of mRNA itself would prevent the target site from being accessible to miRNAs. On the contrary, factors that promote the release of RBP from binding to complimentary sequences could form the stem-loop structure with the target sites that would increase the accessibility of the mRNA target site. The better binding affinity of RISC with target sites could help release other translational repressors from the target site to increase their accessibility.27miRNAs and ECsIt has been widely accepted that the initial trigger for the formation of atherosclerosis is mediated by the dysfunction of ECs.28 ECs have many roles within vascular biology, including their production of various factors that influence the aggregation of platelets, smooth muscle growth, inflammation, as well as vascular tone.29 By introducing the endothelial layer to various noxious stimuli, such as proinflammatory cytokines, hypertension/hyperlipidemia, alteration in fluid shear stress, or increased senescence will have ramifications of increased cell activation and dysfunction.28,30,31 The activated EC will begin to express a higher level of adhesion molecules, which will trap leucocytes, such as monocytes and T cells, and thus the scene has been set, for the continued progression of an atherosclerotic plaque.28,30,32,33 miRNAs, because they play a crucial role in influencing the gene expression and overall function of ECs, must also be considered as participants in guiding the detrimental effects of damaging the monolayer.34One way in which miRNAs affect the dysfunction of ECs is through their role in exacerbating EC senescence—a cellular state, which has been attributed as increasing the likelihood of atherogenesis.35,36 There are several miRNAs, including miR-34a, miR-217, and miR-146a, which have been associated with regulating mechanisms involved in EC senescence.37 It has been shown that miR-34a influences the proliferation and differentiation among many types of cells, including primary ECs, where the level of its expression increases during cellular senescence.36–38 This has been attributed to the concept that an overexpression of miR-34a in EC decreases SIRT1 (sirtuin-1) levels. SIRTI1 is a crucial regulator gene of longevity, which acts by protecting cells against oxidative and genotoxic stress and thus preventing stress-induced senescence.36,38 Various studies have noted an increased level of miR-34a in atherosclerotic arteries, which may be because of this miRNA exacerbating EC dysfunction.36 Another miRNA, which has been linked to influencing the expression of SIRT1, is miR-217. This is an miRNA expressed in both human aortic and coronary artery ECs and has been found to be progressively expressed in the cells of the endothelium during aging. It targets the 3′UTR of SIRT1 to inhibit its protein expression and thus reduces its gain-of-function effects, to improve longevity and vascular disease resistance.35,39,40 MiR-200c has also been shown to affect, in response to reactive oxygen species,41 the expression of proteins that influence proliferation arrest, apoptosis, and senescence within certain vascular endothelium. They are said to target zinc finger E-box–binding homeobox 1, whose reduced expression will influence the pathways responsible for hastening EC senescence42 (Figure 1).Download figureDownload PowerPointFigure 1. miRNAs regulate endothelial senscense and inflammation in response to cytokines, metabolic stimuli, and disturbed flow. miRNAs, such as miR-34a, miR-217, and miR-146, mediate proatherotic factor-induced suppression of the key antisenescence factor SIRT1 (sirtuin-1) transcript in endothelial cells (ECs). Reactive oxygen species (ROS)–sensitive miRNA, such as miR-200c, mediated inhibition of SIRT1, MnSOD (manganese superoxide dismutase), and CAT (catalase) and enhancement in endothelial sensense by downregulating ZEB1 (zinc finger E-box–binding homeobox 1) or FOXO1 (forkhead box protein O1) transcription. Shear stress enhanced miR-19a impairs the cellular self-repair by inhibition of cyclin D. Endothelial miR-19a is also transferred in microparticles and mediates proinflammation response in neighboring adipocytes in a paracrine manner. Moreover, disturbed flow and hyperlipidemia decrease miR-21 and mir-126 expression in ECs, resulting in derepression of NF-κB (nuclear factor κB) medicate VCAM-1 (vascular cell adhesion molecule-1) production, which triggers inflammation. c-JUN indicates a protein encoded by the JUN gene; IKK, IκB kinase; IRAK, interleukin-1 receptor-associated kinase; MP, microparticles; PVAT, perivascular adipose tissue; SOCS3, suppressor of cytokine signaling 3; TNF-α, tumor necrosis factor-α; and TRAF, TNF receptor-associated factor.Moreover, as aforementioned, we are aware that several noxious stimuli will result in an increased inflammatory response being induced within the endothelial layer. It has also been suggested that miRNAs are able to control the inflammatory state of vasculature, by influencing the activation and infiltration of leukocytes via the vascular wall.34,43 A key one involved is miR-126, which has been shown to be important in affecting both vascular dysfunction and its inflammatory state.42 Studies have shown that miR-126 inhibits VCAM-1 (vascular cell adhesion molecule-1). Thus, an inhibition of miR-126 would result in an increased expression of proinflammatory TNF-α (tumor necrosis factor-α) expression, which will increase the activity of NF-κB (nuclear factor κB) and stimulate the activity of VCAM-1, resulting in increased leukocyte-EC interactions that drive the formation of lesions.29,44–46 It has also been noted that the expression of different miRNAs will change in response to an alteration in flow patterns within the vasculature.46 An introduction of laminar shear stress increases the level of miR-19a, which inhibits the expression of cyclin D1, by binding to its 3′ UTR. This results in the EC being kept in a low proliferative state and is hence unable to repair itself.47,48 MiR-21 was also induced in response to a disruption in flow pattern and is believed to be responsible for increasing the levels of several proinflammatory targets, including VCAM-1, which will enhance the dysfunction of the endothelial layer to attract leukocytes, further increasing the likelihood for the initiation of an atherosclerotic plaque34,42 (Figure 1).It is also worth exploring the effect of microparticles, which are the main carriers of miRNAs and are predominantly derived from ECs and platelets. A study noted that introduction of an increased level of microparticles carrying MiR-19b was associated with augmenting the progression of atherosclerosis, by stimulating high levels of macrophage, lipid, and smooth muscle content to enter atherosclerotic plaques.49 It is understood that MiR-19b, carried by endothelial derived microparticles, promotes inflammation within perivascular adipose tissue, by downregulating the expression of its target gene to translate SOCS3 (suppressor of cytokine signaling 3). This is a signal transduction inhibitory molecule, which is crucial to negatively regulate the JAK (Janus kinase)/STAT (signal transducers and activators of transcription) pathway, to control the inflammatory process occurring within vascular cells. Therefore, by inhibiting the activity of SOCS3 within perivascular adipose tissue, MiR-19b promotes the secretion of inflammatory cytokines and macrophage intrusion into the endothelial layer, promoting the progression of atherosclerotic lesion.49miRNAs and SMCsSMCs play a key role in maintaining the functions on vasculature. Alterations leading to apoptosis, senescence, or phenotypic changes have all been attributed to promoting inflammation and vascular disease progression.50 One particular phenotypic change, which SMCs can undergo is the conversion from a contractile to a secretory, which results in SMCs displaying different markers and exhibiting cell functions similar to those of a macrophage.51 This phenotypic switching of SMCs may exacerbate atherosclerosis by having an induced ability to take up lipids and necrotic debris, as well as having an impaired autophagy control; all of which will promote the inflammatory environment necessary for the progression of atherosclerosis and hypertension.10,52,53Recently, it has been indicated that miR-22 influences both phenotypic modulation and neointima formation involving SMCs with the level of expression of this miRNA, differing between both phenotypic states.20,54,55 The varying levels of miR-22 were believed to be transcriptionally regulated through the action of TGF (transforming growth factor)-β1, most likely involving a p53-dependant mechanism. Observations of SMCs transfected with miR-22 inhibitor demonstrated an increased ability of growth, proliferation, and migration. MiR-22 is believed to influence phenotypic change by influencing the expression of 3 genes: MECP2 (methyl CpG-binding protein 2), HDAC4 (histone deacetylase 4), and EVI1 (ecotropic virus integration site 1). It is well understood that miR-22 targets MECP2 during the process of SMC differentiation from stem cells. The inhibition of both MECP2 and HDAC4 in SMCs mimics the effect of an overexpression of miR-22 during phenotypic modulation. The target gene EVI1 also has its synthesis suppressed via the binding of miR-22 to its 3′UTR. It is believed that EVI1 acts as an inhibitory influence on the expression of 5 SMC genes and 2 transcription factors, 1 of which has been shown to act as a transcriptional repressor of contractile genes within the muscle cells.54 It has thus been concluded that miR-22 does carry an influence over the change of SMCs, from a contractile to synthetic nature, most likely through the effects of the suppression of its various target genes, MECP2, HDAC4, and EVI1.50,54Other known miRNAs responsible for regulating SMC differentiation include miR-143 and miR-145, both of which are decreased in diseased vessels. This suggests that a reduction in the expression of these miRNAs may contribute to the dedifferentiation of SMCs that influence the formation of the lesion responsible for the progression of atherosclerosis.56,57 Accelerated SMC proliferation can be discerned in both vascular injury and in the early formation of an atherosclerotic plaque.50,58 Mir-21 has been associated with enhancing proliferation and influencing apoptosis in SMCs and has also been associated with being crucial for the expression of SMC-specific genes.52,59 It has been observed that diseased vessels release a myriad of factors involved in the progression of vascular disease, including the aforementioned NF-κβ and angiotensin II, which induces the expression of miR-21.56 It is believed that TPM1 (tropomyosin 1) is a target gene of miR-21 within SMCs. TPM1 is part of a family of actin-binding proteins, which are essential for the maintenance of the contractile unit, as well as for the regulation of the shape and function of the SMCs. Therefore, as miR-21 will downregulate TPM1 expression, there will be a loss of cytoskeletal stability, which is believed to be responsible for the increased proliferation and migration.59 Other miRNAs, which have been associated with inducing proliferation in SMCs, include miR-26a, miR-34a, miR-130a, and miR-22118; however, their contribution toward the formation of vascular lesions is yet to be determined (Figure 2).Download figureDownload PowerPointFigure 2. The role of miRNAs in proliferation and differentiation of smooth muscle cell (SMC) in atherosclerosis. During mechanical, metabolic, and inflammation stress, upregulated miR-22 inhibits SMC proliferation and carries SMC transformation from a contractile to synthetic nature. The upregulated miR-21 inhibits TPM1 (tropomyosin 1) expression, which can increase SMC proliferation. During atherosclerosis, miRNAs are induced in SMCs and further participate in regulating SMC differentiation either from a contractile to synthetic or vice versa, therefore, modulating the progression of disease. miR-143/145, miR-1, and miR-10a are able to halt the differentiation to synthetic phenotype by suppressing various genes as indicated in the figure. Although miR-126, miR-21, and miR-22 could facilitate the transition and promote atherosclerosis, the increase of miR-126 could also be a result of microparticle-mediated transmission from neighboring endothelial cell. MiR-1 and miR-10 were increased during embryonic stem cells to SMC differentiation. ACE indicates angiotensin-converting enzyme; BCL2, B-cell lymphoma 2; DOCK, dedicator of cytokinesis; ELK1, ETS domain-containing protein Elk-1; EVI1, ecotropic virus integration site 1 protein homolog; FOXO3, forkhead box protein O3; HDAC4, histone deacetylase 4; IRS1, insulin receptor substrate 1; KLF4/5, Kruppel-like factor 4/5; MECP2, methyl CpG-binding protein 2; PDCD4, programmed cell death 4; PIM1, proto-oncogene serine/threonine-protein kinase pim-1; and SRF, serum response factor; TGF-β, transforming growth factor-β.miRNAs in SMC DifferentiationRecently, accumulating evidence indicates a potential contribution of vascular resident stem cells to SMC accumulation in atherosclerotic lesions.60–63 These stem/progenitor cells can migrate into the intima where they differentiate into SMCs via chemokines and cytokines.64–70 miRNAs are necessary for the differentiation of SMCs as demonstrated by the study of Dicer deletion experiments, which resulted in the failure of miRNA maturation.71,72 Dicer deletion in vascular SMCs caused embryonic lethality at days 16 to 17, with extensive internal hemorrhage generated by reduction of SMC proliferation and impaired contractility, which could be partly rescued by overexpression of miR-145.71MiR-143/145Both in vitro and in vivo loss-of-function studies have shown that miR-143/145 is important for SMC differentiation.73,74 Through the repression of antagonistic factor (Klf [Kruppel-like factor] 4, Klf5, Elk1 [ETS domain-containing protein], versican, and angiotensin-converting enzyme) gene expression in the SMC differentiation process, miR-143/145 facilitates expression of SMC-specific genes.75–79 MiR-143 and miR-145 are expressed in proximity in chromosome 5 and share the same promotor, which contains CArG elements, as with most contractile SMC-specific genes. Thus, miR-143/145 is regulated in an SRF (serum response factor)-CArG–dependent pathway. Briefly, for the induction of miR-143/145, TGFβ signals through the Smad2/3 pathway, and myocardin is required to promote binding of SRF to the CArG element, and BMP4 (bone morphogenetic proteins) signals through RhoA pathway, and MRTF-A (myocardin-related transcription factor A) translocation to the nucleus is required.76 PDGF-BB (platelet-derived growth factor), which is known as a synthetic SMC phenotype inducer, activates Src through PDGF receptor and as a result, p53,80 which is an inducer of miR-143/145, is repressed.81 In summary, miR-143/145 is critical for SMC differentiation.MiR-1MiR-1 was observed to be steadily increased in the differentiation process from embryonic stem cells to SMCs, and loss-of-function study showed that miR-1 was essential to the process. MiR-1 induces SMC differentiation through the repression of Klf482 and Pim-1 (pim-1 oncogene; a serine/threonine kinase),83 which also serves as a negative regulator of SMC differentiation. Upstream regulators include myocardin, whose overexpression resulted in significant induction of miR-1.83 However, contradictory data were also observed, which demonstrated that exogenous miR-1 inhibited contractility of SMCs and repressed the expression of contractile proteins.84 Further studies are needed for the elucidation of miR-1 function in SMC differentiation.MiR-21MiR-21 was also involved in TGFβ- and BMP4-induced SMC differentiation by downregulating PDCD4 (programmed cell death 4), which is a repressor of SMC contractile genes.22 DOCK (dedicator of cytokinesis) protein superfamily was also identified as the target of miR-21, whose downregulation inhibited cell migration.85 Mature miR-21 could be increased by the recruitment of TGFβ- and BMP4-specific SMAD signal transducers to the DROSHA complex, which facilitated the processing of pri-miR-21 to precursor miR-21.22 However, there was still evidence that miR-21 could be repressed by increased miR-143 through repression of FRA-1 (fos-related antigen 1) in SMC differentiation86 suggesting the complex regulatory role of miR-21. MiR-21 has also been investigated in many tissues outside of the vasculature, and its function is suggested to be highly context dependent.87MiR-10aRetinoic acid induces SMC differentiation from embryonic stem cells during which process miR-10a was increased.88 This increase is the direct result of retinoic acid-induced nuclear translocation of NF-κβ. Upregulated miR-10a binds to the 3′-UTR of HDAC4, which is a negative regulator of SMC differentiation.88 The regulatory function of miRNAs in SMC differentiation is summarized in Figure 2.OthersOther miRNAs that contribute to SMC differentiation, proliferation, and migration include miR-10089 and miR-125b.90,91 Furthermore, various miRNAs are involved in the promotion of a synthetic phenotype of SMCs, such as miR-24,92 miR-26a,58 miR-31,93 miR-146a,94 miR-204,95 miR-208,96 and miR-221.97 In summary, miRNAs play a critical role in SMC differentiation and represent an important therapeutic choice for cardiovascular diseases.98miRNAs and Monocytes/MacrophagesThe progression of atherosclerosis is driven through the accumulation of lipid-laden macrophage foam cells in the inner arterial wall, which will fuel a state of chronic inflammation that promotes the formation of the plaque.99 To maintain lipid homeostasis, phagocytosis of lipid residues is critical, and dysregulation can drive various pathological diseases, including atherosclerosis.59,99 One key miRNA involved in lipid phagocytosis is miR-33, which is believed to downregulate crucial effectors and transcriptional activators, including FOXO3 (forkhead box protein O3) and TFEB (transcription factor EB), resulting in reduced phagocytosis and lysosomal activity within macrophages. Furthermore, miR-33 also targets ABCA1 (ATP-binding cassette transporter), which results in the restriction of lipid residue metabolism and cholesterol efflux out of macrophages, potentially influencing the growth of atherosclerotic plaques, because of their effects against macrophage autophagy.99,100 Conversely, miR-302 is also believed to regulate the activity of ABCA1 and promotes the efflux of cholesterol, to act as a potential therapeutic agent to decrease the progression of lipid-laden atherosclerotic plaques.99It is a well-understood concept that during times of increased stress, a higher abundance of energy substrates is crucial to mount an effective counterresponse. For macrophages involved in an atherosclerotic plaque, this stress comes in the form of an accumulation of cholesterol that it must attempt to remove via effective efflux pathways.100,101 This pathway is dependent on efficient and lucrative mitochondrial ATP production. Thus, any dysregulation to this process, within a damaged vessel, can spur on the accumulation of lipid droplets within macrophages, building up the foam cells that fill the growing atherosclerotic plaque. MiR-33 has also been associated with assisting in the downregulation of HADHB (mitochondrial trifunctional protein) and CROT (peroxisomal carnitine O-octanoyltransferase), both of which are involved in fatty acid oxidation—a crucial component of cel